Arteritis is an indication for drug development with over 8 pipeline drugs currently active. According to GlobalData, preregistered drugs for Arteritis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Arteritis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Arteritis

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Arteritis overview

Arteritis refers to the inflammation of arteries, which are the blood vessels that carry oxygenated blood from the heart to the rest of the body. Inflammation of these vessels can lead to various symptoms and complications, depending on the type of arteritis and the arteries affected. The cause of arteritis is believed to involve an abnormal immune response leading to inflammation of the arterial walls and genetic factors and environmental triggers may play a role.

For a complete picture of PTSR and LoA scores for drugs in Arteritis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.